生命科学资讯
生物技术与制药领域的最新动态
NIH Director Jay Bhattacharya to take over as temporary CDC chief: media reports
参议院健康委员会主席提出FDA改革方案。
Senate HELP Committee chair pitches proposals for FDA reform
儿科医生血液中提取出抗呼吸道病毒新药潜力物质
Blood from pediatricians yields potential new medicines for respiratory viruses
FDA在迅速重新考虑后接受Moderna流感疫苗申请。
FDA accepts filing for Moderna flu vaccine after swift rethink
诺华与环肽生物技术公司达成逾17亿美元心血管药物合作协议。
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Sensei通过发现Faeth及其二期癌症药物,从悬崖边缘退后一步。
Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug
专注于肠道健康的Rasayana以3600万美元许可协议引进胃肠道候选药物。
Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal
丹纳赫以99亿美元收购患者监护专家马西莫。
Danaher buys patient monitoring specialist Masimo in $9.9B deal
礼来支付CSL 1亿美元预付款,购买在器官移植三期研究中失败的IL-6抗体。
Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
科萨纳携1.75亿美元及抗淀粉样蛋白抗体进军拥挤的阿尔茨海默病领域
Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
免疫学CRO RoukenBio与AVS Bio签署协议,提升抗体开发可预测性。
Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
细胞疗法公司拟募资9200万美元,有望终结东京生物科技IPO荒。
Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
勃林格殷格翰在审查囊性纤维化数据后停止吸入基因疗法研发。
Boehringer axes inhaled gene therapy after viewing cystic fibrosis data
赛诺菲与梯瓦合作研发的IBD药物长期数据展现"关键机遇"。
Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data
指南针引领迷幻疗法在抑郁症治疗中取得第二项关键性胜利,推动审批进程加速。
Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
Cyrano在中期嗅觉丧失试验中获胜后,关键性试验即将展开。
Cyrano noses toward pivotal trial after midphase smell loss win
Novocure获FDA批准,电场疗法瞄准胰腺癌治疗。
Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
吉利德以15亿美元与中国亘喜生物达成最新合成致死疗法协议。
Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
2026年生物制药融资展望:PitchBook预测将迎来“持续而审慎”的复苏。
Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook